The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Synthetic, medicinal, combinatorial, pharmaceutical, natural product, peptide, protein and computational chemistry, including protein engineering, for therapeutic applications
- Purifications, large-scale synthesis, and production of biological molecules, peptides, proteins, or drugs
- Computational approaches to drug discovery
- Assays in support of drug development, including early pharmacological screenings
Shared Interests and Overlaps
There are shared interests with Bioanalytical Chemistry, Biophysics, and Assay Development (IMST (10)). Applications with a focus on the technology/development of an assay may be assigned to IMST (10). Applications using or refining an assay but more focused on the end-product (drug or therapeutic) may be assigned to BCMB (10). Applications focused on a protein engineering technology may be assigned to IMST (10), whereas applications focused on protein engineering for drug discovery may be assigned to BCMB (10). Aptamers used in the development of an assay may be assigned to IMST (10), whereas aptamer chemistry may be assigned to BCMB (10).
There are shared interests with Cell and Molecular Biology (IMST (15)). Applications developing new cell-based technologies and assays may be assigned to IMST (15). Applications using cells for drug discovery or pharmacological screenings may be assigned to BCMB (10).
There are shared interests with Computational, Modeling, and Biodata Management (IMST (14)). Applications that are focused on the general topics of software development for molecular simulations, cheminformatics analysis, and data modeling may be assigned to IMST (14). Applications proposing to apply computational techniques to the discovery and development of new drugs may be assigned to BCMB (10).